Back to Authors

Boytim, Ella

Mayo Clinic

University of Minnesota

Citations 2

Comprehensive analysis of androgen production, uptake, and conversion (APUC) genes to highlight SRD5 family diversity in a large localized prostate cancer cohort.
Shi, Xiaolei, Alshalalfa, Mohammed , Boytim, Ella, Karnes, R. Jeffrey, Spratt, Daniel Eidelberg, Lacuna, Kristine Peregrino , Halabi, Susan, Sharifi, Nima , Tang, Chad, Ross, Ashley, Davicioni, Elai, Antonarakis, Emmanuel S., Ryan, Charles J. , Tran, Phuoc T., Hwang, Justin, Halabi, Susan , Lacuna, Kristine P. , Halabi, Susan , Karnes, R. Jeffrey , Shetty, Amol Carl , Bergom, Hannah E. , Patel, Krishnan R. , Tang, Chad , Davicioni, Elai , Antonarakis, Emmanuel S.

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 382-382

10.1200/jco.2026.44.7_suppl.382 Get It

382 Background: Androgen receptor signaling drives prostate cancer (PC) progression, and genes involved in androgen production, uptake, and conversion (APUC) are key therapeutic targets. We previously defined a 6-APUC gene set ( HSD3B1, HSD3B2, CYP3A43, CYP11A1, CYP11B1, and CYP17A1 ), that identified metastatic PC with favorable prognosis and predict docetaxel benefit. However, the expression landscape and clinical relevance of APUC genes have not been interrogated in localized PC. Methods: We analyzed the expression of 21 APUC genes in 55,329 radical prostatectomy tumor samples that underwent Decipher prostate genomic classifier (GC) testing (Veracyte Inc) between 2016-2024. Baseline clinical/pathologic factors were retrieved from Decipher GRID database (NCT02609269). Associations between gene expression quartiles with PathoGenomic Risk Factors (PGRF) including Very High Decipher score >0.85 (VHD), Grade Group (GG) 4-5, LNI and SVI were examined. Associations with distant metastatic (DM) outcomes and metastasis free survival (MFS) were evaluated using logistic regression in Mayo545 and Cox regression in Meta855 RP cohorts, respectively. Results: High expression of SRD5A2 was associated with favorable PGRF (lower odds ratio (OR), p<0.0001), lower rate of development of DM (OR 0.36, p<0.05), and longer MFS (Hazard ratio (HR) 0.51, p<0.05). HSD17B6 showed similar results for PGRF (lower OR, p<0.0001), DM (OR 0.58, p<0.05) and longer MFS (HR 0.39, p<0.05) despite being associated with GG4-5 and SVI+ in samples with VHD. In contrast, high expression of SRD5A3 and HSD17B10 had high OR for PGRFs (p<0.0001). High expression of SLCO2B1 , an androgen uptake gene, had the strongest association with GG4-5 and SVI/LNI (p<0.001 for both). We noted that SRD5A2 lacked correlation with SRD5A1 and SRD5A3 , which instead correlated with each other. Compared to all APUC genes, SRD5A2 had limited correlations with almost all APUC genes, including ones that exhibited robust cross correlation with each other . Similar to our prior finding, most APUC genes demonstrated negative correlation with AR expression and AR activity signatures. Key outcomes were validated based on transcriptomic data from 492 samples from TCGA database. Conclusions: Comprehensive analysis of 21 APUC genes in over 55,000 PC identified distinct, context-dependent associations with metastatic outcomes and clinical and molecular risk factors. Notably, high SRD5A2 expression was associated with lower odds of high-risk features and metastatic outcomes, whereas SRD5A1 and SRD5A3 linked to adverse outcomes, suggesting critical yet divergent roles among 5-alpha-reductase family members. These findings underscoring androgen-metabolic heterogeneity and highlighting SRD5A2 as a potential biomarker of indolent biology in localized prostate cancer.
Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors
Ali, Atef , Luo, Christine, Plagens, Rosemary N. , Zhang, Bin, Elliott, A., Boytim, Ella, Zorko, Nicholas, Heath, Elisabeth I. , Patnaik, Akash, VanderWalde, A., Antonarakis, Emmanuel S., Miller, Jeffrey S., Hwang, Justin H., Cichocki, Frank, Hwang, Justin H. , Patnaik, Akash , Elliott, Andrew , Zorko, Nicholas A. , Lozada, John R , Ali, Atef , Luo, Christine , Plagens, Rosemary N , Zhang, Bin , Elliott, Andrew , Boytim, Ella , Zorko, Nicholas A , Heath, Elisabeth I , Patnaik, Akash , VanderWalde, Ari , Antonarakis, Emmanuel S , Miller, Jeffrey S , Hwang, Justin H , Cichocki, Frank , Vanderwalde, Ari M. , Antonarakis, Emmanuel S. , Miller, Jeffrey S.

Cancer Immunology Research | February 27, 2026 | Volume: 14 | Issue: 6 | Pages: 1008-1021

10.1158/2326-6066.cir-25-1229 Get It

Abstract Natural killer (NK) cells represent key effectors of antitumor immunity, yet emerging evidence highlights populations with distinct roles in cancer. Despite such expanded diversity within the NK cell repertoire, we lack an understanding of how this heterogeneity affects immune responses and downstream clinical outcomes. Using single-cell RNA sequencing, we systematically profiled NK cells across cancer and uncovered a dichotomous phenotypic and functional landscape of tumor-infiltrating NK cells shaped by opposing intrinsic signaling programs that drive the expression of IFNG or TGFB1. These divergent programs are associated with distinct transcription factor circuits that integrate cues within the tumor microenvironment and skew NK cells toward proinflammatory or suppressive functions. We found that the capacity for NK cells to engage in either functional direction is intrinsically linked to their phenotypic identity. Canonical NK cells recruited from circulation predominantly directed suppressive TGFB1 signals toward effector CD8+ T cells in tumors. Of note, these subsets exhibited higher TGFB1 expression than intratumoral myeloid cells across tumor types. In contrast, a tissue-resident (TR) adaptive subset exhibited exclusively proinflammatory IFNG-driven profiles and was associated with prolonged survival in both primary and metastatic tumor settings. Moreover, these TR adaptive NK cells, but not other subsets, were linked to response to immune checkpoint blockade. Collectively, our study reveals a previously unrecognized regulatory axis in NK cells that shapes NK cell diversity and augments broader antitumor immune responses.